CompletedPhase 3NCT00262782
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- German CLL Study Group
- Principal Investigator
- Michael Hallek, MDMedizinische Universitaetsklinik I at the University of Cologne
- Intervention
- Fludarabine(drug)
- Enrollment
- 877 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 1997 – 2010
Study locations (30)
- Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik, Vienna, Austria
- Hanuschkrankenhaus, Vienna, Austria
- Klinikum St. Marien, Amberg, Germany
- Internistische Praxis - Arnstadt, Arnstadt, Germany
- Zentralklinikum Augsburg, Augsburg, Germany
- Kreiskrankenhaus Aurich, Aurich, Germany
- Regional Hospital Am Plattenwald, Bad Friedrichshall, Germany
- Regional Hospital Bad Hersfeld, Bad Hersfeld, Germany
- Arzt fuer Innere Medizin - Bad Reichenhall, Bad Reichenhall, Germany
- Humaine - Clinic, Bad Saarow, Germany
- Ermstalklinik Bad Urach, Bad Urach, Germany
- Internistische Praxis - Berlin, Berlin, Germany
- Internistische Gemeinschaftspraxis - Berlin, Berlin, Germany
- Haematologisch-Onkologische Schwerpunktpraxis, Berlin, Germany
- Charite - Campus Charite Mitte, Berlin, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00262782 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn